Oral Presentations (5)

The CSF Aβ(1-42)/Aβ(1-40) Ratio Improves the Clinical Utility of Aβ(1-42) By Its Impact at Analytical and Clinical Level.
Sunday, July 16, 2017: 2:00 PM - 3:30 PM
O1-05 Biomarkers: Method Development and/or Quality Control.

Synaptic Markers in Liquor Inversely Correlate with Gray Matter Volume in Cognitively Healthy Individuals.
Sunday, July 16, 2017: 4:15 PM - 5:45 PM.
O1-10 Biomarkers: Prognostic Utility

Clinical Performance of Neurogranin As a Cerebrospinal FLUID Biomarker for Alzheimer’S Disease – an ASSAY Comparison Study.
Sunday, July 16, 2017, 02:45 PM
O1-05: Biomarkers: method development and/or quality control.

Twin Correlations for Amyloid Pathology Measured with Positron Emission Tomography and in Cerebrospinal Fluid in Cognitively Healthy Elderly Monozygotic Twin Pairs.
Monday, July 17, 2017: 2:00 PM - 3:30 PM
O2-05 Biomarkers: Multi-Modal Comparisons

Association Between Nocturnal Amyloid Beta Fluctuations and Sleep.
Monday, July 17, 2017: 2:00 PM - 3:30 PM
O2-04 Development of New Models and Analysis Methods: Neurodegeneration - Associated with Protein Clearance and Metabolism

Posters (11)

Twin Correlations for Amyloid Pathology Measured with Positron Emission Tomography and in Cerebrospinal Fluid in Cognitively Healthy Elderly Monozygotic Twin Pairs.
Alzheimer’s Imaging Consortium: Imaging and Genetics
Saturday, July 15 2017: 12:15 PM - 1:30 PM

Differential Role of CSF Fatty Acid Binding Protein 3, α-Synuclein and Alzheimer’s Disease Core Biomarkers in Lewy Body Disorders and Alzheimer’s Dementia.
Sunday, July 16 Diagnosis and Prognosis: Biomarkers (non-neuroimaging).

Analytical Performance Characteristics of a Novel Immunoassay for the Quantification of BACE-1 in Human Cerebrospinal Fluid.
Sunday, July 16 Diagnosis and Prognosis: Biomarkers (non-neuroimaging).

A Novel Colorimetric ELISA for Quantification of Tau, Phosphorylated at Threonine 181, in Cerebrospinal Fluid.
Sunday, July 16 Diagnosis and Prognosis: Biomarkers (non-neuroimaging).

Analytical Performance Characteristics of a Prototype Immunoassay for Quantification of Alpha-Synuclein in Human Cerebrospinal Fluid.
Monday, July 17 Diagnosis and Prognosis: Biomarkers (non-neuroimaging).

Plasma Amyloid Beta Levels, Cerebral Small Vessel Diseases and Cognition – the Rotterdam Study.
Tuesday, July 18 Diagnosis and Prognosis: Biomarkers (non-neuroimaging).
**Alpha-Synuclein Biomarker Analysis: Analytical Performance and Inter-Laboratory Precision Using a New Colorimetric ELISA.**
*Wednesday, July 19*  Diagnosis and Prognosis: Biomarkers (non-neuroimaging).

**Differences in Analytical Selectivity of β-Amyloid (1-42) Immunoassays Explain Discordant Results in Study Comparisons.**
*Wednesday, July 19*  Diagnosis and Prognosis: Biomarkers (non-neuroimaging).

**Progress on the Development of Certified Reference Materials for Aβ1-42.**
*Wednesday, July 19*  Development topics

**Use for Calibration of Certified Reference Materials for Aβ1-42.**
*Wednesday, July 19*  Development topics

**Associations of Plasma Amyloid Beta Levels with Severity and Progression of Cerebral Small Vessel Disease.**
*Wednesday, July 19*  Development topics